RCKTW — ROCKET PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1281895 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -48,511,000 | -47,594,000 | 285,407,000 | 49,610,000 | 47,368,000 |
| Dec 2025 | 0 | — | -44,031,000 | -42,538,000 | 330,449,000 | 77,558,000 | 53,228,000 |
| Sep 2025 | 0 | — | -52,419,000 | -50,332,000 | 368,033,000 | 75,948,000 | 54,364,000 |
| Jun 2025 | 0 | — | -67,678,000 | -68,919,000 | 420,979,000 | 32,819,000 | 66,768,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-179,618,000
Investing CF
$179,250,000
Financing CF
$147,000
CapEx
$-587,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,488,833,000
Inventory
—
Receivables
—
ST Investments
$94,769,000
EBIT TTM
$-207,491,000
Pretax Income TTM
$-209,383,000
Interest Exp TTM
$1,892,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -228,516,000 | -223,123,000 | 330,449,000 | 53,228,000 | — | -190,014,000 |
| Dec 2024 | 0 | -273,205,000 | -258,746,000 | 527,700,000 | 64,466,000 | — | -209,724,000 |
| Dec 2023 | 0 | -259,659,000 | -245,595,000 | 566,341,000 | 73,767,000 | — | -194,916,000 |
| Dec 2022 | 0 | -223,843,000 | -221,863,000 | 551,807,000 | 62,121,000 | — | -178,142,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.11T | $1246.93 | — |
| JNJ | JOHNSON & JOHNSON | $658.00B | $273.04 | — |
| ABBV | AbbVie Inc. | $467.44B | $264.52 | — |
| MRK | Merck & Co., Inc. | $371.70B | $150.66 | — |
| NVSEF | NOVARTIS AG | $310.96B | $163.60 | — |
News headlines (Yahoo Finance, 1h cache)
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
2026-08-11 18:21 · Yahoo
Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says
2026-08-11 17:36 · Yahoo
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
2026-08-10 20:00 · Yahoo
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
2026-08-03 11:00 · Yahoo
Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?
2026-06-25 12:42 · Yahoo
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
2026-06-12 11:00 · Yahoo
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going?
2026-05-20 12:35 · Yahoo
Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M
2026-05-18 04:50 · Yahoo
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
2026-05-11 15:50 · Yahoo
Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says
2026-05-08 16:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.